ArticleScientific reports2026
Development of loop-mediated isothermal amplification (LAMP)-based assay for rapid detection of fosfomycin resistance gene fosA.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Fosfomycin is an old treatment agent that has been reintroduced as a first-line antibiotic for the treatment of acute uncomplicated urinary tract infections caused by multidrug-resistant bacteria. However, resistance to fosfomycin is rising, and limited options for its detection are available. In this study, we developed a molecular technique based on loop-mediated isothermal amplification (LAMP) as a rapid and easy-to-perform method for the detection of the fosA resistance gene. LAMP primers were designed using the Primer Explorer V5 software. A total of 63 bacterial strains (34 Klebsiella pneumoniae and 29 Escherichia coli) previously characterized by whole genome sequencing, with different MLST and resistant to fosfomycin were used to evaluate the performance of the new LAMP assay. The fosA LAMP-based assay was standardized for optimum primer concentration and time of reaction. Its sensitivity and specificity were also characterized. LAMP products were detected by visual detection (positive reactions turned yellow while negative controls remained pink) and by electrophoresis. Positive LAMP reaction occurred with incubation at 65 °C for 40 min. Nevertheless, amplification products were already observed at 20 min. The overall sensitivity and specificity of the LAMP assay were 90.5% and 90.9%, respectively. For Klebsiella pneumoniae, sensitivity reached 100%, while specificity could not be determined due to the absence of negative samples. In Escherichia coli, sensitivity was 43% and specificity was 90.9%. The limit of detection of LAMP reaction was 8 pg/µL. To the best of our knowledge, this is the first study to develop a LAMP methodology to detect the fosA gene. This LAMP-based assay is a promising rapid molecular method for fosfomycin detection, which could be implemented for on-site analysis in resource-limited settings, with the potential to improve antibiotic therapy interventions for urinary tract infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.